L5 ANSWER 3 OF 3 DGENE (C) 2003 THOMSON DERWENT
AN **AAT88163** cDNA to mRNA DGENE
TI Erythroid Differentiation inducing Activity, EDA, protein - useful to treat disease associated with disorders in differentiation inducing activity of erythropoietic cells
IN Doermer P
PA (GSFU-N) GSF-FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT GmbH.
PI DE 19612463 A1 19971002 38p
AI DE 1996-19612463 19960328
PRAI DE 1996-19612463 19960328
PSL Claim 12; Pages 14-15
DED 20 APR 1998 (first entry)
DT Patent
LA German
OS 1997-481697 [45]
DESC cDNA generated from leukaemic myelomonocyte cell line WEHI-3.
KW Murine; leukaemic myelomonocyte cell line; WEHI-3; ATCC TIB68; DY-8; erythroid differentiation inducing activity; eda; treatment; disease; disorder; erythropoietic cell; inhibitor; antibody; antisense oligonucleotide; therapy; diagnosis; research; probe; ss.
ORGN Mus musculus.
AB **AAT88163**, a consensus partial sequence of a 2200 bp cDNA moleucle generated from a murine leukaemic myelomonocyte cell line WEHI-3 (ATCC TIB68) mRNA, has no continous open reading frames (ORF) and may lack internal sections. AAV04410 is that of another WEHI-3 cDNA clone called DY-8, and contains 640 bp of the 3' region of the erythroid differentiation inducing activity (eda) gene and includes an ORF encoding AAW27721. A novel differentiation inducing protein can be isolated from murine leukaemic myelomonocyte cell lines or irradiated human bone marrow stroma cells, induces differentiation in Friend erythroleukaemia cells resulting in haemoglobin formation, has a molecular weight of 10-60 kD and is inducible by a serum factor present in foetal calf serum. Its corresponding mRNA is expressed in primary cells from thymus, foetal liver, adult spleen or bone marrow and is stably expressed in vitro when an allogeneic spleen cell reaction is performed with non-irradiated, non-pretreated spleen cells from mouse strains CBA and C57B16. Its corresponding cDNA has characteristic repeat structures and AT rich regions, and species of its corresponding mRNA of different sizes have the same 3' region but different 5' regions. The protein can be used to treat diseases associated with disorders in the differentiation inducing activity of erythropoietic cells. It, or an inhibitor, e.g. an antibody or antisense oligonucleotide, can also be used to treat diseases in which local or systemic over or under production of the protein has an influence on the development or progression of disease. A hybrid of the nucleic acid sequence encoding it can be used for therapeutic, diagnostic or research purposes, especially as a molecular probe or antisense molecule to inhibit gene expression.
NA 305 A; 397 C; 390 G; 403 T; 0 other
SQL 1495
SEQ

```
  1 ccgaccgtgc ggacttaaga tggaggcact tcctgtctgc ggcgggaaga
 51 gaaggctcgg tcggagccgg gaatgctggg acttgtagtg cgtagtcaat
```

```
 101 ggttctctat gggctttcag agtgagtggc gggaaggcgg ccccgaggca
 151 tgctgggagt tgtagtcctg ccgtcgtcaa tggttctcta tgggctttca
 201 gagtgagtgg cgggaaggcg gccccgaggc atgctgggag ttgtagtcct
 251 gccatagtca atggttctct atgggctttc agactgagtg gcgggaaggc
 301 ggccccgagg catgctggga gttgcagcgc catgttttaa agcacgcgtt
 351 tctctgtata gacctggctg tggatttttc gctaattctt ttttttagct
 401 ttatttttaa tttttacttt ttcacacagg atttctcttt atagccttgg
 451 ctaccgtttt ttccctaatt attctccttt tcattttggt ttatttttt
 501 ttaattttgg tttttttaag acagggtttc tctgtataga cctggctgtg
 551 gatttctcac taattatttt ttttagcttt atttttaatt tttacttttt
 601 cacacaggat ttctctttat agccttggct accgtttttt ccgtaattat
 651 tcttatttttc attttggttt atttttttaat tttaattttt gattttggag
 701 acagggtttc tcttttagcc gcagctatgg tttctgccct aattattctt
 751 gtccttattt gtaatttaat tcttaattta atttaattta taatttttgtt
 801 gtaagttttt ctgtgggcgt gaatggaaag tctaacccgt gtttctctgt
 851 tcagcgtccg ccggtcacgg ccgccgcccc cagcgacgtc acccacacgc
 901 gcagaagcgg acgccgcggt caagatgtct ctgccatgcc cacgggacgc
 951 acggacgcac ggacggacgg acggactcca caaggtagga agcctgcgcc
1001 gaccgcaccg ccgcacccac cacagcacac aggacacacg cgggcccgc
1051 gcccgcccag gcacacgcgg cacacacggc acacacggca ggcaggccag
1101 gcacacgcat ccgcaggacc cgccgcaccc gccacgcaga cacggacgag
1151 ccgccgcggt caagatgttc acccgccgcg gtcaagatgt atgtgccacc
1201 gaccctcgcc ccgctggacg gacggacgga cgcacgcacg ccgtcagcgt
1251 ccaccggtca ctgccgccgc ccacagtgat gtcacccacg aaagcacaca
1301 cgtagaagcg gacgccgtgg tcaagatgtc tctgccatcc ccacaggacg
1351 gacggacgga ctccacaagg tgcgcgtgtc gccgaggccg ccaggacgga
1401 gcgattctca cggaggaagg agcacgccaa cagggcctga ctgcgtacag
1451 acatgtcccc ctcaataaaa ttgcagttga aatggaaaaa aaaaa
```

L5 ANSWER 2 OF 3 DGENE (C) 2003 THOMSON DERWENT
AN **AAV04410** DNA DGENE
TI Erythroid Differentiation inducing Activity, EDA, protein - useful to treat disease associated with disorders in differentiation inducing activity of erythropoietic cells
IN Doermer P
PA (GSFU-N) GSF-FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT GmbH.
PI DE 19612463 A1 19971002 38p
AI DE 1996-19612463 19960328
PRAI DE 1996-19612463 19960328
PSL Claim 12; Pages 15-16
DED 20 APR 1998 (first entry)
DT Patent
LA German
OS 1997-481697 [45]
CR P-PSDB: AAW27721
DESC cDNA generated from leukaemic myelomonocyte cell line WEHI-3.
KW Murine; leukaemic myelomonocyte cell line; WEHI-3; ATCC TIB68; DY-8; erythroid differentiation inducing activity; eda; treatment; disease; disorder; erythropoietic cell; inhibitor; antibody; antisense oligonucleotide; therapy; diagnosis; research; probe; ss.
ORGN Mus musculus.
AB **AAT88163**, a consensus partial sequence of a 2200 bp cDNA moleucle generated from a murine leukaemic myelomonocyte cell line WEHI-3
(ATCC TIB68) mRNA, has no continous open reading frames (ORF) and may lack internal sections. AAV04410 is that of another WEHI-3 cDNA clone called DY-8, and contains 640 bp of the 3' region of the erythroid differentiation inducing activity (eda) gene and includes an ORF encoding
AAW27721. A novel differentiation inducing protein can be isolated from murine leukaemic myelomonocyte cell lines or irradiated human bone marrow
stroma cells, induces differentiation in Friend erythroleukaemia cells resulting in haemoglobin formation, has a molecular weight of 10-60 kD and is inducible by a serum factor present in foetal calf serum. Its corresponding mRNA is expressed in primary cells from thymus, foetal liver, adult spleen or bone marrow and is stably expressed in vitro when an allogeneic spleen cell reaction is performed with non-irradiated, non-pretreated spleen cells from mouse strains CBA and C57B16. Its corresponding cDNA has characteristic repeat structures and AT rich regions, and species of its corresponding mRNA of different sizes have the same 3' region but different 5' regions. The protein can be used to treat diseases associated with disorders in the differentiation inducing activity of erythropoietic cells. It, or an inhibitor, e.g. an antibody or antisense oligonucleotide, can also be used to treat diseases in which
local or systemic over or under production of the protein has an influence on the development or progression of disease. A hybrid of the nucleic acid sequence encoding it can be used for therapeutic, diagnostic
or research purposes, especially as a molecular probe or antisense molecule to inhibit gene expression.
NA 157 A; 285 C; 212 G; 61 T; 0 other
SQL 715
SEQ
1 cgcgcccgcc cgggatcccc agctgccgcc gcgcccgccc gcccgcccgg

```
  51 ggcccccgct gcagaaccgt gaccgtccgc cggtcacggc cgccgccccc
 101 agcgacgtca cccacacgcg cagaagcgga cgccgcggtc aagatgtctc
 151 tgccatgccc acgggacgca cggacgcacg gacggacgga cggactccac
 201 aaggtaggaa gcctgcgccg accgcaccgc cgcacccacc acagcacaca
 251 ggacacacgc gggccccgcg cccgcccagg cacacgcggc acacacggca
 301 cacacggcag gcaggccagg cacacgcatc cgcaggaccc gccgcacccg
 351 ccacgcagac acggacgagc cgccgcggtc aagatgttca cccgccgcgg
 401 tcaagatgta tgtgccaccg accctcgccc cgctggacgg acggacggac
 451 gcgcgcacgc cgtcagcgtc caccggtcac tgccgccgcc cacagtgatg
 501 tcacccacga aagcacacac gtagaagcgg acgccgtggt caagatgtct
 551 ctgccatccc cacaggacgg acggacggac tccacaaggt gcgcgtgtcg
 601 ccgaggccgc caggacggag cgattctcac ggaggaagga gcacgccaac
 651 agggcctgac tgcgtacaga aatgcccccc ctcaataaaa ttgcagttga
 701 aatggaaaaa aaaaa
```

FEATURE TABLE:

Key	Location	Qualifier
CDS	155..688	*tag= a

L5 ANSWER 1 OF 3 DGENE (C) 2003 THOMSON DERWENT
AN **AAW27721** Protein DGENE
TI Erythroid Differentiation inducing Activity, EDA, protein - useful to treat disease associated with disorders in differentiation inducing activity of erythropoietic cells
IN Doermer P
PA (GSFU-N) GSF-FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT GmbH.
PI DE 19612463 A1 19971002 38p
AI DE 1996-19612463 19960328
PRAI DE 1996-19612463 19960328
PSL Claim 5; Pages 16-17
DED 20 APR 1998 (first entry)
DT Patent
LA German
OS 1997-481697 [45]
CR N-PSDB: AAV04410
DESC Murine erythroid differentiation inducing activity protein.
KW Murine; leukaemic myelomonocyte cell line; WEHI-3; ATCC TIB68; DY-8; erythroid differentiation inducing activity; eda; treatment; disease; disorder; erythropoietic cell; inhibitor; antibody; antisense oligonucleotide; therapy; diagnosis; research; probe.
ORGN Mus musculus.
AB **AAT88163**, a consensus partial sequence of a 2200 bp cDNA moleucle generated from a murine leukaemic myelomonocyte cell line WEHI-3 (ATCC TIB68) mRNA, has no continous open reading frames (ORF) and may lack internal sections. AAV04410 is that of another WEHI-3 cDNA clone called DY-8, and contains 640 bp of the 3' region of the erythroid differentiation inducing activity (eda) gene and includes an ORF encoding AAW27721. A novel differentiation inducing protein can be isolated from murine leukaemic myelomonocyte cell lines or irradiated human bone marrow stroma cells, induces differentiation in Friend erythroleukaemia cells resulting in haemoglobin formation, has a molecular weight of 10-60 kD and is inducible by a serum factor present in foetal calf serum. Its corresponding mRNA is expressed in primary cells from thymus, foetal liver, adult spleen or bone marrow and is stably expressed in vitro when an allogeneic spleen cell reaction is performed with non-irradiated, non-pretreated spleen cells from mouse strains CBA and C57B16. Its corresponding cDNA has characteristic repeat structures and AT rich regions, and species of its corresponding mRNA of different sizes have the same 3' region but different 5' regions. The protein can be used to treat diseases associated with disorders in the differentiation inducing activity of erythropoietic cells. It, or an inhibitor, e.g. an antibody or antisense oligonucleotide, can also be used to treat diseases in which local or systemic over or under production of the protein has an influence on the development or progression of disease. A hybrid of the nucleic acid sequence encoding it can be used for therapeutic, diagnostic or research purposes, especially as a molecular probe or antisense molecule to inhibit gene expression.
AA 22 A; 29 R; 1 N; 9 D; 0 B; 4 C; 12 Q; 4 E; 0 Z; 13 G; 12 H; 1 I; 3 L; 2 K; 3 M; 0 F; 23 P; 9 S; 22 T; 1 W; 1 Y; 6 V; 0 Others
SQL 177

SEQ

```
  1 mptgrtdart dgrtpqgrkp aptapphppq htghtraprp prhtrhtrht
 51 rqagqahasa gpaapatqtr tsrrgqdvhp prsrcmchrp sprwtdgrtr
101 arrqrppvta aahsdvthes thveadavvk mslpspqdgr tdstrcacrr
151 grqdgailte egarqqglta yrnappq
```